Matisse Capital bought a new position in Inflarx NV (NASDAQ:IFRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,902 shares of the company’s stock, valued at approximately $203,000.
Other institutional investors have also bought and sold shares of the company. Citadel Advisors LLC increased its position in Inflarx by 42.1% during the second quarter. Citadel Advisors LLC now owns 190,180 shares of the company’s stock valued at $6,133,000 after acquiring an additional 56,309 shares during the last quarter. Millennium Management LLC purchased a new stake in Inflarx in the second quarter worth about $1,916,000. Redmile Group LLC lifted its position in shares of Inflarx by 138.2% during the second quarter. Redmile Group LLC now owns 2,027,700 shares of the company’s stock valued at $65,393,000 after buying an additional 1,176,600 shares during the last quarter. Baker BROS. Advisors LP lifted its position in shares of Inflarx by 29.4% during the second quarter. Baker BROS. Advisors LP now owns 258,824 shares of the company’s stock valued at $8,347,000 after buying an additional 58,824 shares during the last quarter. Finally, Northern Trust Corp acquired a new position in shares of Inflarx during the first quarter valued at about $228,000. Institutional investors and hedge funds own 54.80% of the company’s stock.
IFRX has been the topic of a number of recent analyst reports. ValuEngine upgraded Inflarx from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Zacks Investment Research upgraded Inflarx from a “sell” rating to a “hold” rating in a report on Tuesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Inflarx has an average rating of “Buy” and an average price target of $42.67.
Shares of NASDAQ IFRX traded up $1.88 during trading on Thursday, hitting $27.90. 17,751 shares of the company were exchanged, compared to its average volume of 23,262. The firm has a market cap of $609.13 million and a PE ratio of -9.49. Inflarx NV has a 12-month low of $14.93 and a 12-month high of $42.83.
COPYRIGHT VIOLATION NOTICE: “Matisse Capital Buys New Position in Inflarx NV (NASDAQ:IFRX)” was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.baseballdailydigest.com/2018/11/22/matisse-capital-takes-203000-position-in-inflarx-nv-ifrx.html.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Recommended Story: Dividend
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.